Ocvirk 2012.

Methods	Single‐centre RCT 2 arms Quality score: D
Participants	n = 85 Median age: 55 years Metastatic disease: 85% ECOG 2‐3: 6%
Interventions	ECF: epirubicin 50 mg/m² i.v. d 1 + cisplatin 60 mg/m² i.v. d 1 i.v.+ 5‐ FU 200 mg/m²/day continuous infusion d 1‐14, repeated at d 22 ECX: epirubicin 50 mg/m² i.v. d1+ cisplatin 60 mg/m² i.v. d 1 + capecitabine 825 mg/m² orally twice daily d 1‐14, repeated at d 22 Treatment was discontinued in case of disease progression, unacceptable toxicity, or if the patient refused further treatment
Outcomes	Overall survival Response rates Time to progression Toxicity
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The method of sequence generation is not described
Allocation concealment (selection bias)	Low risk	"Randomisation and allocation were done by a registration center"
Incomplete outcome data (attrition bias) efficacy	Low risk	All randomised patients were included in the ITT analysis
Incomplete outcome data (attrition bias) safety	Low risk	All randomised patients were included in the ITT analysis
Selective reporting (reporting bias)	Low risk	N/A ‐ except that TTP rather than PFS reported
Other bias	High risk	Response assessment was done by abdominal ultrasound and/or abdominal CT (not CT of the thorax and abdomen). Both methods are insufficient.
Blinded review of CT/MRI‐scans?	High risk	Response assessment was done by abdominal ultrasound and/or abdominal CT (not CT of the thorax and abdomen). Both methods are insufficient.